RET fusion occurs in 0.2% of solid tumors without concurrent driver mutations; the effect of RET activation is less clear in CRC, but several studies suggest that RET chimeric proteins might be associated with worse prognosis, poor treatment response, and reduced OS [113]. Here, RET is linked to colorectal carcinoma.